Phaseline

Companies › Aminex Therapeutics

Aminex Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 9 registered trials: 5 Phase 2, 4 Phase 1; Oncology, Metabolic and endocrine; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AMXT 1501 Dicaprate
Ornithine decarboxylase (ODC) inhibitor
ODC1Phase 1Melanoma (Skin Cancer); Atypical Teratoid/Rhabdoid TumorFeb 2028
Eflornithine Hydrochloride
Ornithine decarboxylase inhibitor
ODC1Phase 1Melanoma (Skin Cancer); Type 1 Diabetes; Neuroblastoma; Medulloblastoma …Feb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05594563Eflornithine HydrochloridePhase 2Type 1 DiabetesMetabolic and endocrineJun 2027
NCT02679144Eflornithine HydrochloridePhase 2NeuroblastomaOncologyFeb 2028
NCT07287917AMXT 1501 DicapratePhase 1Melanoma (Skin Cancer)OncologyFeb 2028
NCT07287917Eflornithine HydrochloridePhase 1Melanoma (Skin Cancer)OncologyFeb 2028
NCT04696029Eflornithine HydrochloridePhase 2MedulloblastomaOncologyMar 2028
NCT04301843Eflornithine HydrochloridePhase 2NeuroblastomaOncologyOct 2028
NCT06892678Eflornithine HydrochloridePhase 1Osteosarcoma RecurrentOncologyApr 2030
NCT02559778Eflornithine HydrochloridePhase 2NeuroblastomaOncologySep 2030
NCT06465199AMXT 1501 DicapratePhase 1Atypical Teratoid/Rhabdoid TumorOncologyMay 2033

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

ODC1 (2)

Companies with the same targets

Orbus Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.